Abstract
Severe asthma is a high-cost chronic disease with different inflammatory phenotypes, eosinophilic phenotype is the most common. Benralizumab is a monoclonal antibody that targets this phenotype. This study evaluated cost-utility ratio of Benralizumab in patients with severe eosinophilic asthma in Colombia.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
